Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05121038 · ClinicalTrials.gov registry record · Phase 1
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
A Phase 1 study of Colon Cancer and Pancreas Cancer, sponsored by Anup Kasi.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT05121038: Active Phase 1 study of Colon Cancer and Pancreas Cancer, sponsored by Anup Kasi.
NCT05121038 is a Phase 1 study of Colon Cancer and Pancreas Cancer that is active but no longer recruiting, run by Anup Kasi. The registered enrollment target is 50 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05121038, a Phase 1 study of Colon Cancer and Pancreas Cancer, is active but no longer recruiting, sponsored by Anup Kasi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers
Primary Outcome
Adverse Events : Counts and proportions of grade 3 -5 Adverse Events
Conditions Studied
Interventions
- DRUG Panitumumab
- DRUG Folfirinox
- DRUG CEND-1
Study Locations (3)
Kansas
- The University of Kansas Cancer Center (KUCC) - Fairway
- The University of Kansas Cancer Center, Westwood Campus - Kansas City
Missouri
- The University of Kansas Medical Center - North Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What the registry record for NCT05121038 still lists
NCT05121038 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Colon Cancer appearing as the primary indexed condition, and to 3 interventions - of which Panitumumab is the first listed.
NCT05121038 reports a single indexed study location in Kansas, Missouri.
Frequently Asked Questions
What is clinical trial NCT05121038 about?
NCT05121038 is a clinical study titled "CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab". This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers
What is the current status of trial NCT05121038?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2021-10-20. Estimated completion is 2026-09.
What conditions does trial NCT05121038 study?
This clinical trial studies the following conditions: Colon Cancer, Pancreas Cancer, Digestive Cancer.
What interventions are being tested in trial NCT05121038?
The interventions under investigation include: Panitumumab (DRUG), Folfirinox (DRUG), CEND-1 (DRUG).
Who is sponsoring clinical trial NCT05121038?
This trial is sponsored by Anup Kasi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05121038 being conducted?
This trial has 3 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05121038's enrollment target sits among peer trials
50 68th of 97 higher than 27 of 97 other Colon Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colon Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
RECRUITING · Phase 1
-
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI